Oncology

The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.

Simoa® assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.

Oncology Assays
Available for Scientific Research

Latest Publications

Quanterix' digital health solution, Simoa, is changing the way researchers, academics and drug manufacturers measure and detect various forms of cancer at the earliest stage. Quanterix' focus in oncology is growing with a network of academic researchers and pharmaceutical and biotech partners. Learn about Simoa's application in oncology by exploring our scientific publications and journals.

Latest News

09.14
Virtual Meeting October 2-3, 2020 Quanterix will be sponsoring this meeting with a presentation followed with Q&A by Paula Perin, PhD - Senior Field Applications Scientist
08.27
Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, Lu KH, Mok SC and Au-Yeung CL. Cancers 2020, 12(9), 2436

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more